Josh Carlson

Dr. Josh Carlson graduated with his PhD from the Institute for Public Health Genetics in the School of Public Health and Community Medicine at the University of Washington in 2007 and received his Master of Public Health from the same department in 2004. Carlson is an assistant professor in the Pharmaceutical Outcomes Research and Policy Program and an affiliate faculty member at the Fred Hutchinson Cancer Research Center. Dr. Carlson conducted his postdoctoral training in pharmacoeconomics with the University of Washington from 2007-2009.

Dr. Carlson’s current research interests and work to date has primarily focused on the intersection of three areas: 1) genomics and emerging technologies in the field of personalized medicine, 2) uncertainty both in our decision-making processes and as the concept applies to the application of medical technologies in “real world” settings (i.e. outside of clinical trials) including comparative effectiveness research, and 3) economic and policy options to address these uncertainties as we seek to improve our healthcare system and the health of our population.

Education

• PhD in Public Health Genetics, University of Washington
• Master of Public Health in Public Health Genetics, University of Washington
• Bachelor of Arts in Environmental, Population, and Organismic Biology, University of Colorado, Boulder

Research Interests

• Comparative effectiveness research
• Value of information analysis in health technology evaluation
• Biomarker development and implementation

Selected Publications

Carlson JJ, Thariani R, Roth J, Gralow J, Henry NL, Esmail L, Deverka P, Ramsey SD, Veenstra DL. Value of Information Analysis within a Stakeholder-Driven Research Prioritization Process in a US Setting: An Application in Cancer Genomics. Med Decis Making. 2013 May;33(4):463-71.

Carlson JJ, Hansen RN, Dmochowski RR, Globe DR, Colayco DC, Sullivan SD. Estimating the Cost-Effectiveness of OnabotulinumtoxinA for Neurogenic Detrusor Overactivity in the United States. Clin Ther. 2013 Apr;35(4):414-24.

Esmail LC, Roth J, Rangarao S, Carlson JJ, Thariani R, Ramsey SD, Veenstra DL, Deverka P. Getting our priorities straight: a novel framework for stakeholder-informed prioritization of cancer genomics research. Genet Med. 2013 Feb;15(2):115-22.

Sullivan SD, Carlson JJ, Hansen RN. Comparative effectiveness research in the United States: a progress report. J Med Econ. 2013;16(2):295-7

Carlson JJ, Ramsey SD. Proof or principle? On economic modeling to guide genomic testing in metastatic colorectal cancer. J Natl Cancer Inst. 2012 Dec 5;104(23):1779-80.

Yeung K, Carlson JJ. Clinical and Economic Review of Erlotinib in Non-Small Cell Lung Cancer. Expert Rev Pharmacoecon Outcomes Res. 2012 Aug;12(4):411-23.

Deverka P, Schully S, Ishibe N, Carlson JJ, Freedman A, Goddard K, Khoury M, Ramsey SD. Stakeholder Assessment of the Evidence for Cancer Genomic Tests: Insights from 3 Case Studies. Genet Med. 2012 Jul;14(7):656-62.

Roth JA, Carlson JJ. Cost-Effectiveness of Gemcitabine + Cisplatin vs. Gemcitabine Monotherapy in Advanced Biliary Tract Cancer.J Gastrointest Cancer. 2012 Jun;43(2):215-23.

Thariani R, Wong W, Carlson JJ, Garrison L, Ramsey S, Deverka PA, Esmail L, Rangarao S, Hoban CJ, Baker LH, Veenstra DL; for the Center for Comparative Effectiveness Research in Cancer Genomics (CANCERGEN). Prioritization in Comparative Effectiveness Research: The CANCERGEN Experience. Med Care. 2012 May;50(5):388-93.

Thariani R, Veenstra DL, Carlson JJ, Garrison LP, Ramsey S. Paying for Personalized Care: Cancer Biomarkers and Comparative Effectiveness. Mol Oncol. 2012 Apr;6(2):260-6.

Roth JA, Carlson JJ. Prognostic Role of ERCC1 in Advanced Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. Clin Lung Cancer. 2011 Nov;12(6):393-401.

Ishibe N, Carlson JJ, Ramsey SD, Freedman A, Schully S. Use of epidermal growth factor receptor mutation analysis in patients with advanced non-small-cell lung cancer to determine erlotinib use as first-line therapy. PLoS Curr. 2011 Jun 21;3:RRN1245.

Carlson JJ, Wong WB, Veenstra DL, Reyes C. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer. J Med Econ. 2011;14(2):159-66.